Clinical Trial Update: Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity. [Phase 3]

View source ↗

Summary

Open-label long-term extension study of fesoterodine in Japanese subjects with neurogenic detrusor overactivity completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity
• Urinary Bladder Disorders

Drugs mentioned

• Fesoterodine (fesoterodine)

Snippet

Sponsor: Pfizer | Conditions: Urinary Bladder, Neurogenic | Phase 3 | Status: COMPLETED | Results posted: 2020-10-26